Filtros de búsqueda

Lista de obras de

A novel HIV treatment model using private practitioners in South Africa

artículo científico publicado en 2012

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

artículo científico publicado en 2020

Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events

artículo científico publicado en 2008

Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme

artículo científico publicado en 2010

Changing predictors of mortality over time from cART start: implications for care

artículo científico publicado en 2011

Evaluation of a workplace HIV treatment programme in South Africa

artículo científico publicado en 2007

HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa

artículo científico publicado en 2009

Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program

artículo científico publicado en 2008

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

scientific article published on 01 September 2019

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

artículo científico publicado en 2021

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

scientific article published on 30 January 2020

Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa

artículo científico publicado en 2010

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

artículo científico publicado en 2020

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda